ventures
Biotech Finance Across the Lifecycle o2h Ventures supports biotech companies through every stage, from inception to scale. Our SEIS fund provides early, tax-efficient capital to university spin-outs and founders, alongside mentorship and access to our Cambridge network. The Knowledge-Intensive EIS Fund offers follow-on capital to drive clinical and commercial growth. As our portfolio matures, the Seven Sisters Human Health Growth Fund backs de-risked, later-stage biotech companies ready to scale.
The o2h Seven Sisters Human Health Growth Fund
The UK consistently attracts over 40% of all biotech investment across Europe. Yet, despite world-class science, a persistent valuation gap with the US remains, driven not by weaker innovation, but by a shortage of growth capital at the crucial scaling stages.
A Seven later-stage human health companies from the o2h portfolio, with the clearest path to exit
A Clear 5–7 year exit horizon, mainly through trade sales
A Companies which have been significantly technically de-risked, with revenue or late-stage trials
A Access to UK biotech at attractive valuations
A Positioned for growth, scale, and meaningful exits
Our Seven Sisters Human Health Growth Fund will provide an opportunity to invest in some of the UK’s most exciting biotech companies at attractive entry points. Many of these businesses have already navigated significant technical risk, are either generating meaningful revenue or advancing towards late-stage clinical trials and, crucially, are at the stage where a single round of funding could accelerate them towards a clear exit pathway.